Dirk Fischer
Overview
Explore the profile of Dirk Fischer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henzi B, Putananickal N, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, et al.
Neuromuscul Disord
. 2025 Jan;
47:105275.
PMID: 39879732
Most patients with Duchenne muscular dystrophy (DMD) are non-ambulant. Preserving proximal motor function is crucial, rarely studied. Tamoxifen, a selective oestrogen receptor modulator, reduced signs of muscular pathology in a...
2.
Kesenheimer E, Wendebourg M, Weidensteiner C, Sander L, Weigel M, Haas T, et al.
J Neurol
. 2025 Jan;
272(1):102.
PMID: 39775109
Background: With the approval of disease-modifying treatments for 5q-spinal muscular atrophy (SMA), there is an increasing need for biomarkers for disease course and therapeutic response monitoring. Radially sampled Averaged Magnetization...
3.
Henzi B, Lava S, Spagnuolo C, Putananickal N, Donner B, Pfluger M, et al.
Eur J Pediatr
. 2024 Jul;
183(9):4057-4062.
PMID: 38960907
Conclusion: This hypothesis-generating post-hoc analysis suggests that tamoxifen over 48 weeks is well tolerated and may help preserving cardiac structure and function in Duchenne muscular dystrophy. Further studies are justified....
4.
Chiriboga C, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J, et al.
J Neurol
. 2024 May;
271(8):4871-4884.
PMID: 38733387
Risdiplam is a once-daily oral, survival of motor neuron 2 (SMN2) splicing modifier approved for the treatment of spinal muscular atrophy (SMA). JEWELFISH (NCT03032172) investigated the safety, tolerability, pharmacokinetics (PK),...
5.
Timpani C, Kourakis S, Debruin D, Campelj D, Pompeani N, Dargahi N, et al.
JCI Insight
. 2023 Sep;
8(21.
PMID: 37751291
New medicines are urgently required to treat the fatal neuromuscular disease Duchenne muscular dystrophy (DMD). Dimethyl fumarate (DMF) is a potent immunomodulatory small molecule nuclear erythroid 2-related factor 2 activator...
6.
Henzi B, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, Putananickal N, et al.
Lancet Neurol
. 2023 Sep;
22(10):890-899.
PMID: 37739572
Background: Drug repurposing could provide novel treatment options for Duchenne muscular dystrophy. Because tamoxifen-an oestrogen receptor regulator-reduced signs of muscular pathology in a Duchenne muscular dystrophy mouse model, we aimed...
7.
Chiriboga C, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J, et al.
Neurol Ther
. 2023 Jul;
12(5):1799-1801.
PMID: 37395990
No abstract available.
8.
Putananickal N, Gross E, Orsini A, Schmidt S, Hafner P, Gocheva V, et al.
Front Pharmacol
. 2023 May;
14:1172483.
PMID: 37214431
Emerging findings propose that the pathophysiology of migraine may be associated with dysfunctional metabolic mechanisms. Recent findings suggest that migraine attacks are a response to the cerebral energy deficit, and...
9.
Gross E, Putananickal N, Orsini A, Schoenen J, Fischer D, Soto-Mota A
Sci Rep
. 2023 Mar;
13(1):3787.
PMID: 36882474
Emerging evidence suggest migraine is a response to cerebral energy deficiency or oxidative stress in the brain. Beta-hydroxybutyrate (BHB) is likely able to circumvent some of the meta-bolic abnormalities reported...
10.
Chiriboga C, Bruno C, Duong T, Fischer D, Mercuri E, Kirschner J, et al.
Neurol Ther
. 2023 Feb;
12(2):543-557.
PMID: 36780114
Introduction: Risdiplam is a survival of motor neuron 2 (SMN2) splicing modifier for the treatment of patients with spinal muscular atrophy (SMA). The JEWELFISH study (NCT03032172) was designed to assess...